Richman C M, Holt J A, Lorincz M A, Herbst A L
Obstet Gynecol. 1985 Feb;65(2):257-63.
Estrogen receptor in tumor cytosol extracts from primary ovarian adenocarcinomas and/or from their metastatic foci was measured for determination of whether or not estrogen receptor content is preserved after chemotherapy. Tumor tissue was analyzed from 36 patients who had not received chemotherapy and from 16 patients after varying periods of chemotherapy. The percentages of relatively estrogen receptor-rich tumors (with more than 35 fmol estrogen receptor per milligram soluble protein, or with more than 1200 fmol estrogen receptor per gram tissue wet weight) were similar in the two groups (31 and 37%). In three of four patients who had specimens analyzed both before and after chemotherapy, there was little difference between the levels of estrogen receptor in the initial sample and in samples taken after ten to 32 months of chemotherapy. In one patient, a decrease in the amount of receptor after chemotherapy appeared to be related to the sampling technique used. There was no discernible effect of treatment on the prevalence or amount of estrogen receptor in metastases. No correlation was observed between estrogen receptor levels and the histologic type or grade of the tumor or the patients' survival. The data suggest that chemotherapy has little effect on measurable receptor levels in ovarian epithelial carcinomas. When present in one tumor site, receptor can be expected to be present in a majority of other sites in the same patient.
测量原发性卵巢腺癌和/或其转移灶的肿瘤细胞溶质提取物中的雌激素受体,以确定化疗后雌激素受体含量是否得以保留。分析了36例未接受化疗患者以及16例经过不同疗程化疗患者的肿瘤组织。两组中相对富含雌激素受体的肿瘤(每毫克可溶性蛋白中雌激素受体超过35飞摩尔,或每克组织湿重中雌激素受体超过1200飞摩尔)的百分比相似(分别为31%和37%)。在对化疗前后均有标本进行分析的4例患者中的3例,初始样本与化疗10至32个月后采集样本中的雌激素受体水平几乎没有差异。在1例患者中,化疗后受体量的减少似乎与所采用的采样技术有关。治疗对转移灶中雌激素受体的患病率或数量没有明显影响。未观察到雌激素受体水平与肿瘤的组织学类型或分级以及患者生存率之间存在相关性。数据表明,化疗对卵巢上皮癌中可测量的受体水平影响很小。当在一个肿瘤部位存在受体时,可以预期在同一患者的大多数其他部位也会存在受体。